Menu
Recruiting NCT07685405

Identification of Circulating Biomarkers Associated With Extracellular Vesicles in Sarcomas

— Observational Sarcoma, Ewing

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: one blood sample, 3 blood samples.
Who it may be relevant to
Registry conditions: Sarcoma, Ewing. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Feasibility Study for the Identification of Circulating Biomarkers Associated With Extracellular Vesicles in Sarcomas

Overview

The study involves blood samples from patients with Ewing's sarcoma to identify circulating biomarkers as a tool for the preclinical validation of innovative therapeutic approaches

Interventions

  • Other one blood sample
    non onco
  • Other 3 blood samples
    onco

Primary outcome measures

  • characterisation of circulating biomarkers [Time frame: at baseline (time 0); before surgery; after 6 months from surgery]

Eligibility criteria

Inclusion criteria for cancer patients

  • Male and female patients of any age diagnosed with Ewing sarcoma.
  • Signed, study-specific informed consent form for the BIOVES study (cancer patients)

Inclusion criteria for non-cancer patients

  • Male and female patients of legal age without a cancer diagnosis.
  • Signed, study-specific informed consent form for the BIOVES study (non-cancer patients)

Exclusion criteria

Patients who do not meet all inclusion criteria

\-

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Case-control

Study locations

Italy · 1 center
  • Istituto ortopedico Rizzoli Laboratorio di Ricerc Oncologica e Genomica funzioanle — Bologna

Identifiers

NCT: NCT07685405 · BIOVES

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗